FY2026 EPS Forecast for Palvella Therapeutics Cut by Analyst

Palvella Therapeutics, Inc. (NASDAQ:PVLA) – Analysts at HC Wainwright decreased their FY2026 earnings per share (EPS) estimates for shares of Palvella Therapeutics in a research report issued on Wednesday, April 1st. HC Wainwright analyst A. Fein now anticipates that the company will post earnings per share of ($4.41) for the year, down from their prior estimate of ($3.28). HC Wainwright currently has a “Buy” rating and a $270.00 target price on the stock. The consensus estimate for Palvella Therapeutics’ current full-year earnings is ($3.69) per share. HC Wainwright also issued estimates for Palvella Therapeutics’ FY2027 earnings at ($3.76) EPS, FY2028 earnings at $2.08 EPS, FY2029 earnings at $9.00 EPS and FY2030 earnings at $22.29 EPS.

Several other equities research analysts have also recently commented on PVLA. Chardan Capital raised their target price on shares of Palvella Therapeutics from $210.00 to $240.00 and gave the stock a “buy” rating in a research report on Tuesday. Truist Financial set a $210.00 price target on shares of Palvella Therapeutics in a research report on Tuesday, February 24th. Weiss Ratings restated a “sell (d)” rating on shares of Palvella Therapeutics in a report on Monday, December 29th. Raymond James Financial reaffirmed a “strong-buy” rating and set a $193.00 price objective on shares of Palvella Therapeutics in a research report on Tuesday, December 16th. Finally, Stifel Nicolaus set a $250.00 target price on Palvella Therapeutics in a research note on Tuesday, February 24th. One investment analyst has rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $198.07.

Palvella Therapeutics Stock Up 2.6%

NASDAQ:PVLA opened at $123.46 on Friday. The firm’s fifty day simple moving average is $106.43 and its 200 day simple moving average is $92.07. The stock has a market cap of $1.46 billion, a P/E ratio of -33.28 and a beta of -0.20. Palvella Therapeutics has a twelve month low of $18.23 and a twelve month high of $151.18.

Palvella Therapeutics (NASDAQ:PVLA) last announced its earnings results on Tuesday, March 31st. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.13).

Institutional Trading of Palvella Therapeutics

Institutional investors and hedge funds have recently modified their holdings of the stock. Archer Investment Corp purchased a new stake in shares of Palvella Therapeutics in the third quarter valued at approximately $28,000. Group One Trading LLC increased its holdings in Palvella Therapeutics by 151.5% during the 4th quarter. Group One Trading LLC now owns 332 shares of the company’s stock worth $35,000 after purchasing an additional 200 shares during the period. Russell Investments Group Ltd. bought a new stake in Palvella Therapeutics during the 3rd quarter valued at $36,000. JPMorgan Chase & Co. increased its stake in shares of Palvella Therapeutics by 108,066.7% during the second quarter. JPMorgan Chase & Co. now owns 3,245 shares of the company’s stock valued at $73,000 after buying an additional 3,242 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in Palvella Therapeutics during the 2nd quarter valued at about $85,000. Institutional investors own 40.11% of the company’s stock.

Insider Buying and Selling

In other Palvella Therapeutics news, Director Elaine J. Heron purchased 2,400 shares of the firm’s stock in a transaction on Friday, February 27th. The shares were acquired at an average cost of $125.00 per share, for a total transaction of $300,000.00. Following the completion of the transaction, the director owned 47,812 shares of the company’s stock, valued at approximately $5,976,500. The trade was a 5.28% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Kathleen Goin sold 4,302 shares of the stock in a transaction that occurred on Wednesday, March 18th. The shares were sold at an average price of $117.99, for a total value of $507,592.98. Additional details regarding this sale are available in the official SEC disclosure. 20.50% of the stock is currently owned by corporate insiders.

Key Stories Impacting Palvella Therapeutics

Here are the key news stories impacting Palvella Therapeutics this week:

• Positive Sentiment: HC Wainwright raised long‑term EPS forecasts sharply (FY2028 → $2.08, FY2029 → $9.00, FY2030 → $22.29) and reiterated a “Buy” rating with a $270 price target — a bullish signal that implies substantial upside if clinical/financial execution meets those long‑range assumptions. HC Wainwright long-term upgrades
• Positive Sentiment: Coverage note / media mention (Chardan Capital cited by American Banking News) flagged upside potential and said PVLA stock price is expected to rise — additional third‑party bullish commentary that can amplify investor interest. Palvella Therapeutics Stock Price Expected to Rise
• Neutral Sentiment: HC Wainwright published quarterly 2026 EPS schedules (Q1: -$0.89, Q2: -$1.02, Q3: -$1.19, Q4: -$1.30) — useful near‑term reference points for modeling cash burn and runway but confirm continued losses through 2026. Qtr estimates
• Negative Sentiment: HC Wainwright cut near‑term FY2026 and FY2027 EPS estimates (FY2026 revised to -$4.41; FY2027 to -$3.76), signaling a weaker short‑term profit trajectory than previously expected — a headwind for investors focused on nearer‑term fundamentals. Near-term cuts
• Negative Sentiment: Lifesci Capital also lowered FY2026 EPS (to -$6.11), adding another analyst voice forecasting larger near‑term losses, which could increase concern about dilution, additional financing needs, or slower commercialization. Lifesci Capital revision
• Negative Sentiment: Recent reported quarterly results missed EPS expectations (last EPS -$1.08 vs. consensus -$0.95), a reminder of execution risk and a factor that likely makes some investors cautious despite bullish long‑term forecasts.

About Palvella Therapeutics

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.